logo
Plus   Neg
Share
Email

FDA Expands Approval Of Pfizer's Lorbrena As Treatment For ALK-Positive Metastatic Lung Cancer

Pfizer Inc. (PFE) said that the U.S. Food and Drug Administration approved its supplemental New Drug Application or sNDA for Lorbrena or lorlatinib, expanding the indication to include first-line treatment of people with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer or NSCLC. LORBRENA is now indicated for adults with metastatic NSCLC whose tumors are ALK-positive as detected by an FDA-approved test.

The expanded approval of Lorbrena was based on the results from the pivotal Phase 3 CROWN trial, which showed a 72% reduction in risk of progression or death vs. XALKORI in a previously untreated patient population as assessed by blinded independent central review.

Lorbrena is a third-generation ALK inhibitor specifically designed to inhibit the most common tumor mutations that drive resistance to current medications and to address metastases in the brain, a frequent site for disease progression in ALK-positive NSCLC. Up to 40% of people with ALK-positive metastatic NSCLC present with brain metastases at initial diagnosis.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Intel Corp. (INTC) Thursday reported a profit and revenues for the first quarter that trumped Wall Street estimates, driven by continued demand for PCs. Moving ahead, the company lifted its full-year outlook. Santa Clara, California-based Intel reported first-quarter profit of $3.36 billion or $0.82... A third of those American adults now refusing to get vaccinated would get vaccinated if they could take a pill instead of getting the vaccine shot, according to a poll conducted by Quadrant Strategies and commissioned by biotechnology company Vaxart, Inc. A pill vaccine is expected to overcome vaccine resistance of millions of Americans. While reporting financial results for the first quarter on Thursday, Biogen Inc. (BIIB) raised its adjusted earnings guidance for the full-year 2021, but maintained revenue outlook. For fiscal 2021, the company raised its adjusted earnings guidance to a range of $17.50 to $19.00 per share from the...
Follow RTT